RecruitingPhase 1Phase 2NCT07160725

A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors

A Phase 1/2a, First-in-human, Open-label Study of BMS-986517 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors

Sponsor

Bristol-Myers Squibb

Enrollment

540 participants

Start Date

Oct 15, 2025

Study Type

INTERVENTIONAL

Conditions

Solid Tumours

Summary

A phase 1/2a, open-label, first-in-human study mainly aimed to evaluate the safety and tolerability of BMS-986517 in participants with solid tumors

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called BMS-986517 for people with solid tumours. The study is currently recruiting participants at 19 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBMS-986517

Specified dose on specified days

DRUGPumitamig

Specified dose on specified days

Locations(19)

Local Institution - 0033

Irvine, California, United States

USC/Norris Comprehensive Cancer Center

Los Angeles, California, United States

University of California, Irvine (UCI) Health - UC Irvine Medical Center

Orange, California, United States

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

Sanford Cancer Center

Sioux Falls, South Dakota, United States

START - Dallas Fort Worth

Fort Worth, Texas, United States

START San Antonio

San Antonio, Texas, United States

START Mountain Region

West Valley City, Utah, United States

Fred Hutchinson Cancer Center

Seattle, Washington, United States

Herlev and Gentofte Hospital

Copenhagen, Capital Region, Denmark

Odense Universitetshospital

Odense, Region Syddanmark, Denmark

Copenhagen University Hospital Rigshospitalet

Copenhagen, Denmark

National Cancer Center Hospital

Chuo-ku, Tokyo, Japan

Local Institution - 0026

Málaga, Andalusia, Spain

Local Institution - 0022

Badalona, Barcelona [Barcelona], Spain

Local Institution - 0024

Barcelona, Barcelona [Barcelona], Spain

Clinica Universidad de Navarra

Pamplona, Navarre, Spain

Hospital Universitario Fundación Jiménez Díaz

Madrid, Spain

Local Institution - 0023

Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07160725

Related Trials

A Study of BI 3810944 in Patients With Advanced Cancer

NCT072244257 locations

Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations

NCT0658143290 locations

Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours

NCT0744685519 locations

A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab

NCT0739167019 locations

A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors

NCT0678917210 locations